ADC · 방광·요로상피

15개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved15 programs
ADCCurated CoreFDAAstellasMMAE (monomethyl auristatin…Approved

enfortumab vedotin (Padcev, ASG-22ME, enfortumab-vedotin-ejfv)

Locally advanced or metastatic urothelial carcinoma · Nectin-4

#Nectin-4#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 201Status Approved
ADCCurated CoreFDARemeGenMMAEApproved

disitamab vedotin (Disitamab Vedotin, RC48)

HER2+ urothelial, gastric, breast · HER2

#HER2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 159Status Active
ADCStandard DatabasestaleFavrillederuxtecan for metastatic b…Phase 2

Antibody-Drug Conjugate Therapy (Antibody-Drug Conjugate Therapy)

Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis and Ureter Urothelial Carcinoma · FRα

#FR#ADC#Phase2#Popular#antibody-drug-conjugate+5
Trials 58Status Recruiting
ADCLimited DatastaleMerck Sharp & Dohme LLCPhase 1

sacituzumab govitecan (Trodelvy, Sacituzumab)

Muscle Invasive Bladder Urothelial Carcinoma · Muscle Invasive Bladder Urothelial Carci

#MuscleInvasiveBladderUrothelialC#ADC#Phase1#Popular#antibody-drug-conjugate+2
Trials 56Status Active
ADCLimited DatastaleVadim S Koshkinvedotin (BT8009) and dual-A…Phase 1

N803 (Nogapendekin Alfa Inbakicept, Nogapendekin Alfa Inbakicept (N803))

Metastatic Urothelial Carcinoma; Urothelial Carcinoma · Metastatic Urothelial Carcinoma

#MetastaticUrothelialCarcinoma#ADC#Phase1#Popular#antibody-drug-conjugate+4
Trials 53Status Discontinued
ADCLimited DatastaleAstellas Pharma Incvedotin after avelumabPhase 1

Enfortumab (Enfortumab)

Muscle Invasive Bladder Urothelial Carcinoma · Muscle Invasive Bladder Urothelial Carci

#MuscleInvasiveBladderUrothelialC#ADC#Phase1#antibody-drug-conjugate#vedotin+2
Trials 49Status Active
ADCStandard DatabasestaleAstellasPhase 3

EV/P (enfortumab vedotin and pembrolizumab, enfortumab vedotin and pembrolizumab (EV/P))

Advanced Bladder Cancer · Advanced Bladder Cancer

#AdvancedBladderCancer#ADC#Phase3#antibody-drug-conjugate#ADCsandimmunotherapyhavechangedt+1
Trials 47Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Drug: Disitamab Vedotin)

Upper Urinary Tract Urothelial Carcinoma · Upper Urinary Tract Urothelial Carcinoma

#UpperUrinaryTractUrothelialCarci#ADC#Phase2#antibody-drug-conjugate#RemeGen
Trials 26Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Tislelizumab)

Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#Her2OverexpressingHigh-RiskNon-M+1
Trials 17Status Active
ADCLimited DatastaleALX Oncology Inc.Phase 2

Evorpacept (Evorpacept)

Plasma Cell Myeloma Refractory · Bladder Cancer

#BladderCancer#ADC#Phase2#antibody-drug-conjugate#PlasmaCellMyelomaRefractory+1
Trials 14Status Recruiting
ADCLimited DatastaleRemeGenApproved

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin and Gemcitabine)

Radical Cystectomy; Urothelial Carcinoma · Radical Cystectomy

#RadicalCystectomy#ADC#Approved#antibody-drug-conjugate#UrothelialCarcinoma+1
Trials 6Status Active
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin and Toripalimab)

Muscle Invasive Bladder Cancer; HER2 Expression · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#MuscleInvasiveBladderCancer+2
Trials 1Status Active
ADCLimited DatastaleMerckPhase 2

PEV (Pembrolizumab & Enfortumab Vedotin, Pembrolizumab & Enfortumab Vedotin (PEV))

Urothelial Carcinoma · Urothelial Carcinoma

#UrothelialCarcinoma#ADC#Phase2#antibody-drug-conjugate#Merck
Trials 1Status Recruiting
ADCLimited DatastaleFudan UniversityPhase 2

Observational Cohort (Sacituzumab Tirumotecan, Sacituzumab Tirumotecan (Observational Cohort))

Bladder Cancer; Metastatic Urothelial Carcinoma · Bladder Cancer

#BladderCancer#ADC#Phase2#antibody-drug-conjugate#MetastaticUrothelialCarcinoma+1
Trials 1Status Recruiting
ADCLimited DatastaleAstellasPreclinical

pembrolizumab (Keytruda, enfortumab vedotin plus pembrolizumab in first line setting for advanced upper tract urothelial carcinoma)

Advanced Upper Tract Urothelial Carcinoma · Advanced Upper Tract Urothelial Carcinom

#AdvancedUpperTractUrothelialCarc#ADC#Preclinical#antibody-drug-conjugate#Astellas
Trials 1Status Active